	US 12,240,818 B2
	Crystalline forms of plasma kallikrein inhibitors
Sukanto Sinha, San Francisco, CA (US); Tamie Chilcote, San Francisco, CA (US); Julian Scott Northen, South Shields (GB); and Jamie Marshall, Gateshead (GB)
Assigned to Rezolute, Inc., Redwood City, CA (US); and ActiveSite Pharmaceuticals, Inc., San Francisco, CA (US)
Filed by Rezolute, Inc., Redwood City, CA (US); and ActiveSite Pharmaceuticals, Inc., San Francisco, CA (US)
Filed on Mar. 14, 2022, as Appl. No. 17/694,543.
Application 17/694,543 is a division of application No. 16/922,064, filed on Jul. 7, 2020, granted, now 11,306,061.
Claims priority of provisional application 62/871,517, filed on Jul. 8, 2019.
Prior Publication US 2022/0380315 A1, Dec. 1, 2022
Int. Cl. C07D 231/14 (2006.01)

CPC C07D 231/14 (2013.01) [C07B 2200/13 (2013.01)]

11 Claims

1. An amorphous form of 1-benzyl-N-(4-carbamimidoyl-benzyl)-1H-pyrazole-4-carboxamide acetate, Form V, characterized by an XRPD pattern that is substantially similar to the pattern in FIG. 5.